

In the Claims

Claims 1-24 (Cancelled)

Claim 25 (Currently amended): A method for the treatment or prevention of a Group B *Streptococcal* infection, wherein said method comprises administering to a patient in need of such treatment or prevention, an immunogenically effective amount of an isolated ~~bacterial~~ Group B *Streptococcal* non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase.

Claim 26 (Cancelled)

Claim 27 (Previously presented): The method, according to claim 25, wherein the infection is a local infection.

Claim 28 (Previously presented): The method, according to claim 25, wherein the infection is a urinary tract infection.

Claims 29-31 (Cancelled)

Claim 32 (Currently amended): The method, according to claim 25, wherein the isolated ~~bacterial~~ Group B *Streptococcal* non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase comprises the amino acid sequence of SEQ ID NO:12.

Claims 33-35 (Cancelled)

Claim 36 (Previously presented): The method, according to claim 25, wherein the patient is human.

Claims 37-44 (Cancelled)

Claim 45 (Currently amended): A method for raising antibodies against Group B *Streptococcus*, comprising administering ~~an isolated peptide comprising the amino acid sequence of SEQ ID NO:12 to a patient in need thereof~~ an isolated Group B *Streptococcal* non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase to a subject, wherein the ~~peptide~~ non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is administered in an amount effective to produce the antibodies.

Claim 46 (Cancelled)

Claim 47 (New): The method, according to claim 45, wherein the non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase comprises SEQ ID NO:12.

Claim 48 (New): The method, according to claim 25, wherein the patient is female and the non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is administered to protect against Group B *Streptococcal* infection.

Claim 49 (New): The method according to claim 25, wherein the patient is female, and wherein the non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is administered to the female during pregnancy to protect against Group B *Streptococcal* infection.

Claim 50 (New): The method according to claim 25, wherein the patient is a neonate, and wherein the non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is administered to the mother of the neonate, prior to pregnancy with the neonate, to protect against Group B *Streptococcal* infection.

Claim 51 (New): The method according to claim 25, wherein the patient is a neonate, and wherein the non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase is

administered to the mother of the neonate, during pregnancy with the neonate, to protect against Group B *Streptococcal* infection.